Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms

被引:123
作者
Sulak, PJ
Cressman, BE
Waldrop, E
Holleman, S
Kuehl, TJ
机构
[1] TEXAS A&M UNIV,SCOTT & WHITE MEM HOSP & CLIN,HLTH SCI CTR,COLL MED,DEPT PATHOL,TEMPLE,TX 76508
[2] TEXAS A&M UNIV,SCOTT & WHITE MEM HOSP & CLIN,HLTH SCI CTR,COLL MED,DEPT MED BIOCHEM & GENET,TEMPLE,TX 76508
关键词
D O I
10.1016/S0029-7844(96)00488-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To test the hypothesis that extending the number of consecutive active oral contraceptives (OC)s given will decrease the frequency of menstrual-related problems including dysmenorrhea, menorrhagia, premenstrual-type symptoms, and menstrual migraines. Methods: A prospective analysis was designed to track the experiences of 50 women taking OCs and experiencing menstrual-related problems. Fifty consecutive patients, who were taking OCs and had symptoms during the pill-free interval, were followed in a multispecialty clinic by an individual physician and nurse practitioner team. The patients were permitted to extend the number of consecutive active OCs to delay menstrual-related symptoms. Results: Immediate outcome of the 50 patients revealed 74% (37 patients) stabilized on an extended regimen of 6 to 12 weeks of consecutive days with active OCs. Twenty-six percent (13 patients) either discontinued OCs or returned to the standard regimen with 3 weeks of active pills. Of the 37 patients who were stabilized on an extended regimen, 27 have completed thus far between five and 13 extended cycles with 6-23 months of follow-up (mean 16 months). Conclusion: Experience in a series of 50 OC users with menstrual-related symptoms demonstrated that delaying menses by extending the number of consecutive days of active pills is well tolerated and efficacious. We believe that a large prospective study is warranted to further our knowledge in this area. Copyright (C) 1997 by The American College of Obstetricians and Gynecologists.
引用
收藏
页码:179 / 183
页数:5
相关论文
共 7 条
[1]   LONG-INTERVAL TREATMENT REGIMEN WITH A DESOGESTREL-CONTAINING ORAL-CONTRACEPTIVE [J].
CACHRIMANIDOU, AC ;
HELLBERG, D ;
NILSSON, S ;
WALDENSTROM, U ;
OLSSON, SE ;
SIKSTROM, B .
CONTRACEPTION, 1993, 48 (03) :205-216
[3]   POSTPONEMENT OF WITHDRAWAL BLEEDING IN WOMEN USING LOW-DOSE COMBINED ORAL-CONTRACEPTIVES [J].
HAMERLYNCK, JVTH ;
VOLLEBREGT, JA ;
DOORNEBOS, CM ;
MUNTENDAM, P .
CONTRACEPTION, 1987, 35 (03) :199-205
[4]   THE ACCEPTANCE OF A 7-WEEK CYCLE WITH A MODERN LOW-DOSE ORAL-CONTRACEPTIVE (MINULET) [J].
KORNAAT, H ;
GEERDINK, MH ;
KLITSIE, JW .
CONTRACEPTION, 1992, 45 (02) :119-127
[5]  
KOVACS GT, 1994, BR J FAM PLANN, V19, P294
[6]   ACCEPTABILITY OF AN ORAL-CONTRACEPTIVE THAT REDUCES FREQUENCY OF MENSTRUATION - TRI-CYCLE PILL REGIMEN [J].
LOUDON, NB ;
FOXWELL, M ;
POTTS, DM ;
GUILD, AL ;
SHORT, RV .
BRITISH MEDICAL JOURNAL, 1977, 2 (6085) :487-490
[7]   WOMENS ATTITUDES TO WITHDRAWAL BLEEDING AND THEIR KNOWLEDGE AND BELIEFS ABOUT THE ORAL-CONTRACEPTIVE PILL [J].
RUTTER, W ;
KNIGHT, C ;
VIZZARD, J ;
MIRA, M ;
ABRAHAM, S .
MEDICAL JOURNAL OF AUSTRALIA, 1988, 149 (08) :417-419